首页> 美国卫生研究院文献>PLoS Clinical Trials >A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products
【2h】

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products

机译:一种可靠且经过验证的LC-MS / MS方法,可同时定量40种消费品中的4种大麻素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the past 50 years, Cannabis sativa (C. sativa) has gone from a substance essentially prohibited worldwide to one that is gaining acceptance both culturally and legally in many countries for medicinal and recreational use. As additional jurisdictions legalize Cannabis products and the variety and complexity of these products surpass the classical dried plant material, appropriate methods for measuring the biologically active constituents is paramount to ensure safety and regulatory compliance. While there are numerous active compounds in C. sativa the primary cannabinoids of regulatory and safety concern are (-)-Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and their respective acidic forms THCA-A and CBDA. Using the US Food and Drug Administration (FDA) bioanalytical method validation guidelines we developed a sensitive, selective, and accurate method for the simultaneous analysis CBD, CBDA, THC, and THCA-A in oils and THC & CBD in more complex matrices. This HPLC-MS/MS method was simple and reliable using standard sample dilution and homogenization, an isocratic chromatographic separation, and a triple quadrupole mass spectrometer. The lower limit of quantification (LLOQ) for analytes was 0.195 ng/mL over a 0.195–50.0 ng/mL range of quantification with a coefficient of correlation of >0.99. Average intra-day and inter-day accuracies were 94.2–112.7% and 97.2–110.9%, respectively. This method was used to quantify CBD, CBDA, THC, and THCA-A in 40 commercial hemp products representing a variety of matrices including oils, plant materials, and creams/cosmetics. All products tested met the federal regulatory restrictions on THC content in Canada (<10 μg/g) except two, with concentrations of 337 and 10.01 μg/g. With respect to CBD, the majority of analyzed products contained low CBD levels and a CBD: CBDA ratio of <1.0. In contrast, one product contained 8,410 μg/g CBD and a CBD: CBDA ratio of >1,000 (an oil-based product). Overall, the method proved amenable to the analysis of various commercial products including oils, creams, and plant material and may be diagnostically indicative of adulteration with non-hemp C. sativa, specialized hemp cultivars, or unique manufacturing methods.
机译:在过去的50年中,紫花苜蓿(C. sativa)已从世界范围内基本禁止的物质发展为一种在许多国家在文化和法律上都被药用和娱乐用途接受的物质。由于其他司法管辖区将大麻产品合法化,并且这些产品的种类和复杂性超过了传统的干植物材料,因此测量生物活性成分的适当方法对于确保安全和法规遵从性至关重要。苜蓿中存在许多活性化合物,但监管和安全方面的主要大麻素为(-)-Δ⁹-四氢大麻酚(THC),大麻二酚(CBD)以及它们各自的酸性形式THCA-A和CBDA。使用美国食品药品监督管理局(FDA)的生物分析方法验证指南,我们开发了一种灵敏,选择性和准确的方法,可同时分析油脂中的CBD,CBDA,THC和THCA-A,以及更复杂的基质中的THC和CBD。使用标准样品稀释和均质,等度色谱分离和三重四极杆质谱仪,此HPLC-MS / MS方法简单可靠。在0.195-50.0 ng / mL的定量范围内,分析物的定量下限(LLOQ)为0.195 ng / mL,相关系数> 0.99。日内和日间平均准确度分别为94.2–112.7%和97.2–110.9%。该方法用于量化40种代表各种基质(包括油,植物原料和乳膏/化妆品)的商业大麻产品中的CBD,CBDA,THC和THCA-A。测试的所有产品均符合加拿大联邦法规对四氢大麻酚含量的限制(<10μg/ g),其中两种除外,分别为337和10.01μg/ g。关于CBD,大多数分析产品的CBD水平较低,且CBD:CBDA比<1.0。相反,一种产品包含8,410μg/ g的CBD和CBD:CBDA比率> 1,000(油基产品)。总体而言,该方法被证明适用于各种商业产品的分析,包括油,霜和植物材料,并且可能在诊断上指示使用非大麻苜蓿,专业大麻品种或独特的制造方法进行掺假。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号